ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Rapid screening of mutations for second-line-drug-resistant genes in Mycobacterium tuberculosis culture isolates by in-house developed DNA bio-chip.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rapid Extensively Drug-Resistant (XDR) TB Diagnosis: An In-House DNA Biochip for Drug Resistance Detection and Mutation Profiling ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rate of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has been steadily increasing and is a major setback to TB control in India. The availability of quick and reliable methods for detecting second-line drug resistance (SLDR) is vital to managing patients satisfactorily. A rapid molecular technique to detect SLDR in Mycobacterium tuberculosis (M. tuberculosis) has been developed using DNA biochip.
methodsSpecific probes containing wild-type region or specific mutations were designed for immobilization on DNA bio-chip. DNA bio-chip was developed in-house on polycarbonate track-etched membranes (PC-TEM). DNA bio-chip allows the identification of mutations in gyrA gene for fluoroquinolone (FQ) resistance, in rrs gene and the eis promoter region for resistance to second-line injectable drugs (SLID). An asymmetric multiplex PCR was standardized for gyrA, rrs and eis genes. A chemiluminescence based biochip assay was optimized. Bio-chip was tested on 112 M. tuberculosis clinical isolates with different resistance spectra.
resultsIsolates analyzed using bio-chip shows that 61 (61%) samples were wild-type. Twelve samples show mutations in gyrA gene, 11 samples in rrs gene, 12 samples in eis gene and 4 samples show double mutation in rrs and eis genes. The sensitivity and specificity of bio-chip for detection of FQ resistance ranged from 75 to 100% and 96.7%-100%, respectively. The sensitivity and specificity of SLID detection ranged from 90.9 to 100% and 96.7-100% respectively. The analytical sensitivity of the bio-chip was ~ 250 genome copies per assay.
conclusionThe biochip has high sensitivity and specificity and could be useful for clinical microbiology studies and epidemiological surveillance of drug resistant (DR) M. tuberculosis. It is a highly accurate tool for screening for SLDR, significantly reducing the time for phenotypic drug susceptibility test (DST) results from weeks to a single day.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.